Alcon will showcase its latest surgical innovations and clinical data at the AAO meeting in Chicago later this week.

This includes the company's latest tool for glaucoma treatment, the Voyager Direct Selective Laser Trabeculoplasty (DSLT). Like selective laser trabeculoplasty (SLT), the Voyager delivers laser energy to the trabecular meshwork. The Voyager's proprietary eye-tracking technology therapy ensures an accurate, automated treatment delivery through the limbus, according to a company press release, eliminating the need for a gonio lens or manual aiming necessary to conduct SLT. The Voyager DSLT was formerly the Belkin Eagle. Meeting attendees can visit Alcon at booth #4008 for hands-on demonstrations. 

Alcon will also introduce two handheld gas delivery systems, the UNIFEYE and the UNIPEXY. In the UNIFEYE, surgeons can have have confidence in the gas-to-air mixture by integrating all components for gas delivery in one handheld device. The result is improved accuracy via a predictable, precise gas-to-air ratio that mitigates the risk of delivering an unintended gas-to-air mixture, as well as a simplified and streamlined setup, eliminating the manual attachment of gas cylinders and filters that have historically wasted time and gas, said the company in a press release.

The UNIPEXY is portable, designed for in-clinic convenience. Like the UNIFEYE, it contains an integrated single-dose pico-cylinder comprised of perfluoropropane (C₃F₈) or sulfur hexafluoride (SF₆) that puts everything needed to perform pneumatic retinopexy in the surgeon’s hand. Both systems will be available for demonstration at the Alcon booth.

Finally, new data from the COMET 2 and 3 for AR-15512 (acoltremon ophthalmic solution 0.003%) will be presented. The investigational drug treats the signs and symptoms of dry eye disease. The Phase 3 results will be featured in an electronic poster titled "AR-15512: A Novel TRPM8 Agonist for the Treatment of the Signs and Symptoms of Dry Eye.”